Summary
AbbVie Inc. reported strong revenue growth in the third quarter of 2020, driven significantly by the recently completed acquisition of Allergan. Net revenues surged to $12.9 billion, a substantial increase from $8.5 billion in the prior year period, largely due to the inclusion of Allergan's operations. Despite the revenue uplift, the company faced increased operating costs and expenses, including significant amortization of intangible assets and integration costs related to the Allergan acquisition. Diluted earnings per share (EPS) for the quarter were $1.29, showing a slight increase from $1.26 in the prior year, however, this figure includes substantial one-time charges and non-cash expenses. Excluding these, the operational performance might present a different picture. Investors should focus on the revenue diversification achieved through the Allergan merger and monitor the integration progress and synergy realization to gauge the long-term impact on profitability and shareholder value. The company also reiterated its commitment to returning capital to shareholders with a planned dividend increase.
Financial Highlights
56 data points| Revenue | $12.90B |
| Cost of Revenue | $5.05B |
| Gross Profit | $7.85B |
| SG&A Expenses | $2.85B |
| Operating Expenses | $9.65B |
| Operating Income | $3.25B |
| Interest Expense | $630.00M |
| Net Income | $2.31B |
| EPS (Basic) | $1.30 |
| EPS (Diluted) | $1.29 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1AbbVie completed the acquisition of Allergan on May 8, 2020, significantly expanding its diversified product portfolio across immunology, oncology, aesthetics, neuroscience, and eye care.
- 2Total net revenues for the third quarter of 2020 increased by 52.1% to $12.9 billion, largely driven by the inclusion of Allergan's operations.
- 3For the nine months ended September 30, 2020, net revenues grew by 30.7% to $31.9 billion.
- 4Diluted earnings per share (EPS) for the third quarter of 2020 were $1.29, an increase from $1.26 in the prior year period.
- 5Operating earnings for the third quarter were $3.3 billion, up from $2.6 billion in the prior year, but impacted by increased operating costs and expenses.
- 6The company continues to invest heavily in research and development, with pipeline assets across immunology, oncology, aesthetics, neuroscience, eye care, and women's health.
- 7AbbVie announced a planned increase in its quarterly cash dividend from $1.18 to $1.30 per share, demonstrating a commitment to returning capital to shareholders.